After Hours
$
43.03
Change
-1.98 -4.40%
Volume
Volume 32,260
Mar 2, 2021, 6:08 p.m.
Quotes are delayed by 20 min
Previous close
$ 46.47
$ 45.01
Change
-1.46 -3.14%
Day low
Day high
$44.49
$46.72

52 week low
52 week high
$12.71
$56.40

Market cap
$6.29B
Average volume
1.43M
P/E ratio
49.93
Rev. per Employee
$1.97M
EPS
0.90
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on HALO
-
Halozyme Therapeutics stock price target raised to $59 from $46 at Benchmark
- Tomi Kilgore
-
Halozyme Therapeutics started at buy with $39 stock price target at Benchmark
- Tomi Kilgore
-
Charting market cross currents, S&P 500 maintains 200-day average
- Michael Ashbaugh
-
Charting market cross currents, S&P 500 survives test of 200-day average
- Michael Ashbaugh
-
Charting a ‘rabbit from hat’ reversal, S&P 500 maintains the May range
- Michael Ashbaugh
-
Charting a bullish reversal, S&P 500 presses 20-day average ahead of Fed
- Michael Ashbaugh
-
Halozyme Therapeutics upgraded to outperform from market perform at BMO Capital
- Tomi Kilgore
-
Halozyme Therapeutics stock price target raised to $24 from $17 at BMO Capital
- Tomi Kilgore
-
Halozyme licenses Enhanze to Roche for new targets
- MarketWatch.com
-
Bull trend intact, U.S. benchmarks knife from well-defined support
- Michael Ashbaugh
-
- Barron's Online
-
Halozyme's stock soars after Bristol-Myers license deal
- Tomi Kilgore
-
Halozyme's stock soars 13% in premarket trade after Bristol-Myers license deal
- Tomi Kilgore
-
Halozyme to receive $105 mln upfront, potential royalties from Bristol-Myers as part of license deal
- Tomi Kilgore
-
Halozyme enters license pact with Bristol-Myers
- Tomi Kilgore
-
Halozyme shares fall after secondary share offering annoucned
- Wallace Witkowski
-
Halozyme started at market perform with $14 stock price target at BMO Capital
- Tomi Kilgore
-
- Barron's Online
-
Halozyme Therapeutics started at buy with $12 stock price target at Deutsche Bank
- Tomi Kilgore
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For January 24, 2018
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For April 17, 2017
- Benzinga.com
-
- Benzinga.com
Other News on HALO
-
Halozyme Therapeutics prices $700M of private debt offering
- Seeking Alpha
-
10-K: HALOZYME THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Halozyme: Nice Pivot To A Royalty Business
- Seeking Alpha
-
Notable earnings after Tuesday's close
- Seeking Alpha
-
Halozyme Therapeutics Q4 2020 Earnings Preview
- Seeking Alpha
-
- CNW Group
- Loading more headlines...
Earnings Announcement
Press Releases on HALO
-
Are These Top Health Care Stocks Worth Watching Ahead Of March?
- StockMarket.com
-
Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
- PR Newswire - PRF
-
Halo Announces Pricing of Overnight Marketed Offering of Units
- GlobeNewswire
-
Halo Collective Announces Overnight Marketed Offering of Units
- GlobeNewswire
-
Halo Announces Pricing of Overnight Marketed Offering of Units
- GlobeNewswire
-
Halo Collective Announces Overnight Marketed Offering of Units
- GlobeNewswire
-
Global Emphysema Market Size, Share, Industrial Growth Status and Global Outlook 2020 to 2028
- Market Insight Reports
-
Halozyme Raises Full Year 2020 Guidance
- PR Newswire - PRF
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com